InFocus Therapeutics
InFocus Therapeutics is a company specializing in integrated RNA drug discovery, leveraging a novel discovery platform to identify new RNA drugs at an unprecedented scale and throughput. The company is committed to transforming RNA-targeted drug discovery through innovation and disruptive technology.
Industries
Nr. of Employees
small (1-50)
Products
Integrated RNA drug discovery platform
A platform combining high-throughput discovery workflows to identify RNA-targeted small-molecule therapeutic candidates at scale.
InFocus Artificial Intelligence Discovery Engine
A second-generation AI-powered discovery platform designed to identify differentiated RNA-targeting small molecules faster, integrating scientific rigor with international business development and capital formation.
Integrated RNA drug discovery platform
A platform combining high-throughput discovery workflows to identify RNA-targeted small-molecule therapeutic candidates at scale.
InFocus Artificial Intelligence Discovery Engine
A second-generation AI-powered discovery platform designed to identify differentiated RNA-targeting small molecules faster, integrating scientific rigor with international business development and capital formation.
Expertise Areas
- RNA drug discovery
- Small-molecule RNA modulation
- Oncology therapeutic discovery
- High-throughput screening
Key Technologies
- RNA-targeted small-molecule discovery
- High-throughput discovery platforms
- Integrated drug discovery workflows
News & Updates
Our efforts to develop innovative RNA-targeting small molecule therapeutics for patients in oncology will be greatly accelerated by PSCC’s top experts in the academic-to-industry continuum, with comprehensive network and infrastructure to data, technologies, laboratories and funding support.
InFocus was selected amongst over 1,300 startups into the prestigious Berkeley SkyDeck Pad-13 Program. Our CSO will represent the company to join the three-month program starting in May 2024. As a Pad-13 member, the InFocus team receives exclusive access to world-class resources from the SkyDeck Program as well as the faculty and alumni network of UC Berkeley.
Our efforts to develop innovative RNA-targeting small molecule therapeutics for patients in oncology will be greatly accelerated by PSCC’s top experts in the academic-to-industry continuum, with comprehensive network and infrastructure to data, technologies, laboratories and funding support.
InFocus was selected amongst over 1,300 startups into the prestigious Berkeley SkyDeck Pad-13 Program. Our CSO will represent the company to join the three-month program starting in May 2024. As a Pad-13 member, the InFocus team receives exclusive access to world-class resources from the SkyDeck Program as well as the faculty and alumni network of UC Berkeley.